Wearable Technology in Clinical Trials 2026: Digital Endpoints, FDA COA Qualification, and Real-Time Safety Monitoring

Wearable devices have been generating clinical-grade physiological data for years — continuous heart rate, ECG, blood oxygen, activity, sleep — but the translation of that data into regulatory-accepted clinical trial endpoints has moved slowly. The FDA's COA (Clinical Outcome Assessment) qualification process for digital measures is the bottleneck: sponsors need to demonstrate that the wearable-derived endpoint measures what it claims to measure, is sensitive to meaningful clinical change, and is interpretable by patients as well as regulators. Several digital biomarkers have completed or are near completing the qualification process in 2026, which changes what's possible in decentralized trial design.

FDA-Qualified Digital Endpoints by Therapeutic Area

The COA Qualification Process: What Sponsors Must Demonstrate

For a digital endpoint to be accepted as a primary or key secondary endpoint in a regulatory submission, it must be qualified as a Clinical Outcome Assessment (COA) — demonstrating both validity (it measures what it claims to measure) and reliability (it measures consistently across populations and settings).

The FDA's Digital Health COA qualification pathway (via DHCoE and CDER/CBER collaboration) requires:

• Concept of interest (COI) definition: A precise, testable definition of what the endpoint measures — e.g., "spontaneous free-living gait speed during habitual activities in the home environment" rather than the generic "mobility."
• Measurement equivalence study: A study demonstrating that the digital endpoint captures the same construct as the established clinical comparator — e.g., that wearable-derived gait speed correlates with timed 10-meter walk test at a pre-specified threshold.
• Meaningfulness to patients: Patient focus groups and Rasch analysis demonstrating that changes in the digital endpoint correspond to changes patients would identify as meaningful in their daily life — the same patient-focused drug development requirement applied to PRO instruments.

Real-Time Safety Monitoring: The Operational Advantage

Beyond endpoint measurement, wearable devices in 2026 trials are generating continuous safety data that fundamentally changes adverse event detection timelines. Specific applications with demonstrated impact:

• Cardiac safety in oncology trials: Continuous ECG monitoring via wearable patch detects QTc prolongation and arrhythmias within hours of drug administration — versus the standard 12-lead ECG at scheduled visits (typically every 4 weeks). Real-time cardiac monitoring has enabled same-day dose holds in multiple oncology Phase 1 trials, preventing serious cardiac adverse events.
• Fall detection in neurology trials: Wearable accelerometers detecting fall events in Parkinson's, MS, and ALS trials provide safety data that patients frequently under-report in diaries. Automated fall detection showed 3x higher event capture versus patient-reported diaries in a 2024 comparative study (NEJM Evidence).
• Sleep-safety signal integration: In CNS trials targeting insomnia, anxiety, or depression, overnight actigraphy detects sleep fragmentation as a potential adverse effect of investigational drugs — providing a sensitive early signal that may not appear in once-weekly clinical assessments.